Japanese encephalitis vaccines: Newer vaccines and their current status.
Keywords:
Japanese encephalitis, Flavivirus, VaccinationAbstract
Japanese encephalitis is a serious arboviral disease caused by virus of genus Flavivirus. Japanese encephalitis is the most common vaccine preventable virus causing encephalitis in Asia. There is no antiviral treatment for patients with Japanese encephalitis and clinical care is only supportive management. Thus vaccination is the best prevention against J a p a n e s e e n c e p h a l i t i s . A n u m b e r o f developments have occurred in the vaccines available for JE including widespread availability of inactivated Vero cell vaccine, live attenuated vaccine, live chimeric vaccine. Thus the improved access to JE vaccines and availability of newer vaccines necessitates revision of JE vaccines.
Downloads
References
Japanese Encephalitis Vaccines: WHO position paper – February 2015. Wkly Epidemiol Rec. 2015 Feb 27;90(9):69–87
Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, Present, and Future of Japanese Encephalitis. Emerg Infect Dis. 2009;15(1):1–7.
Japanese encephalitis: status of surveillance and immunization in Asia and Western Pacific, 2012. WHO Weekly Epidemiological Record. 2013;34 (88):357–364
Wang H, Liang G. Epidemiology of Japanese encephalitis; past, present, and future p r o s p e c t s . T h e r C l i n R i s k M a n a g. 2015;11:435–48.
Fischer M, Lindsey N, Staples E, Hills S, CDC. J a p a n e s e E n c e p h a l i t i s V a c c i n e s : Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59:1–27.
Paulke-Korinek M, Kollaritsch H, Kundi M, Z w a z l I , S e i d l - F r i e d r i c h C , J e l i n e k T.Persistence of antibodies six years after booster vaccination with inactivatedvaccine against Japanese encephalitis. Vaccine 2015;33(30):3600–4.
Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C,et al. Chimeric live, attenuated vaccine against Japanese encephalitis(ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge withinactivated Japanese encephalitis antigen. J Infect Dis. 2003;188(8):1213–30.
Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, et al. Single dose ofSA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case–control study i n N e p a l e s e c h i l d r e n 5 y e a r s a f t e r immunization. Vaccine. 2007;25(27):5041–5.
The Australian Immunisation Handbook. 10th e d . C a n b e r r a : A u s t r a l i a n G o v e r n m e n t Department of Health, 2013.
Salisbury D, Ramsay M, Noakes K. (eds). Immunisation against infectiousdisease. London. Chapter 20 Japanese encephalitis pg 201–7.
Rappleye WC (1939) Epidemiology of J a p a n e s e B e n c e p h a l i t i s . Epidemicencephalitis: Third Report of the M a t h e s o n C o m m i s s i o n , C o l u m b i a UniversityPress: New York.
Pond WL, Smadel JE (1954) Neurotropic viral diseases in the Far East duringthe Korean War. Med Sci Publ Army Med Serv Graduate Sch 4: 219-233.
Endy TP, Nisalak A (2002) Japanese encephalitis virus: Ecology andepidemiology, in Japanese Encephalitis and West Nile Viruses, J Mackenzie,ADT Barrett, and V. Deubel, Editors. Springer-Verlag: Berlin. p. 11-48.
Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, et al. (1996) Anoutbreak of Japanese encephalitis in the Torres Strait, Australia. Med JAustralia 1995. 165: 256-260.
Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, et al. (1999) Japaneseencephalitis in north Queensland, Australia, 1998. Med J Australia 170: 533-536.
Mitamura T (1936) Study on Japanese encephalitis virus. Animal experimentsand mosquito transmission experiments. Kansui Iji 1: 260-270.
Holbrook MR, ADT Barrett (2002) Molecular epidemiology of Japaneseencephalitis virus, in Japanese Encephalitis and West Nile Viruses, JSMackenzie, Barrett, ADT and Deubel V, Editor Springer-Valag: Berlin-Heidelberg. 75-90.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
